090-71-3415

Caris - MI Profile, tissue (FFPE) **

Tissue/ Formalin-fixed paraffin-embedded (FFPE) block

Received specimen to report 30 days (Slide received to report)

Caris Molecular Intelligence uses multiple tumor profiling technologies to decode cancer. This technology agnostic, panomic approach allows our medical teams to more fully understand the biology of the tumor – therefore helping oncologists’ better plan their attack.

PD-1 (test by IHC) is an immunosuppressive protein molecule that is upregulated on activated T-cells and other immune cells. It is activated by binding to its ligand, PD-L1, an action that results in intracellular responses that reduce T-cell activation. Reports of aberrant PD-L1 expression in cancer cells have spurred the development of PD-1 and PD-L1 inhibitors. The U.S. Food and Drug Administration (FDA) recently approved an anti-PD-1 therapy, pembrolizumab (Keytruda), for the treatment of advanced or unresectable melanoma. Another anti-PD-1 agent, nivolumab, was recently approved in Japan for the treatment of unresectable melanoma.

MMR genes create a system for recognizing and repairing mistakes that arise during DNA replication. If the MMR genes themselves become damaged or mutated, they will not work properly and the mistakes made during replication will not be repaired. This leaves the cell vulnerable and unhealthy. Cells without normal MMR genes can develop more and more mistakes with each new copy, resulting in a normal healthy cell losing the ability to stop dividing, or growing, once it has appropriately replaced itself. The ability to stop dividing, or growing, is what causes a colon cell to become cancerous. 

Next-generation sequencing (NGS)

All Biomarker Analysis includes:
DNA Mutation, Copy Number Alterations, Insertions/Deletions    
Genomic Signatures: MSI, TMB
RNA Fusion Analysis
Pyro sequencing
In situ hybridization
IHC: PD-L1, MMR

Comprehensive Genomic Profiling, Tissue